Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Algernon Pharmaceuticals  (AGN) has filed a pre-IND meeting request with the U.S. Food and Drug Administration
  • Algernon is planning a phase 2 study of NP-120 (Ifenprodil) for the treatment of chronic cough
  • Algernon could begin its phase 2 chronic cough study as early as Q2 of 2022
  • Algernon is a clinical-stage pharmaceutical development company that investigates safe, approved drugs for new disease applications
  • Algernon Pharmaceuticals Inc. (AGN) opened trading at C$0.08 per share

Algernon Pharmaceuticals  (AGN) has filed a pre-IND meeting request with the U.S. Food and Drug Administration.

Algernon is planning a phase 2 study of NP-120 (Ifenprodil) for the treatment of chronic cough. Ifenprodil is an NMDA GluN2B subunit inhibitor and may represent a potential treatment for chronic cough.

Depending on the feedback from the U.S. FDA, the company could begin its phase 2 chronic cough study as early as Q2 of 2022. 

“This submission to the U.S. FDA underscores our commitment to patients with refractory chronic cough,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals Inc.

“Many of these patients experience a significant negative impact on their quality of life, and there are currently no approved treatments.”

Algernon is a clinical-stage pharmaceutical development company that investigates safe, approved drugs for new disease applications.

Algernon Pharmaceuticals Inc. (AGN) opened trading at C$0.08 per share.

More From The Market Herald

" Top 5 Stories of the Week: Rover Metals (TSXV:ROVR), Datametrex (TSXV:DM), Argentina Lithium (TSXV:LIT), good natured Products (TSXV:GDNP)

Canada’s main stock index continued its downward trend with a fourth straight day of losses on Friday, driven to one-month lows as crude

" LevelJump Healthcare (TSXV:JUMP) announces $2.5M private placement

LevelJump Healthcare (JUMP) will be conducting a non-brokered private placement financing for gross proceeds of up to $2,500,000.

" Leveljump Healthcare (TSXV:JUMP) provides corporate update

Leveljump Healthcare (JUMP) has agreed to acquire an additional minority interest in Real Time Medical (RTM), Shaw Lens, and Shaw Vision.
The Market Herald Video

" Datametrex AI (TSXV:DM) plans to roll up the AI industry

Datametrex AI (DM) announced plans to implement a roll up strategy focused on Artificial Intelligence companies in 2022.